Proposed removal of low volume or discontinued substances from the Revised In Commerce List

Official title: Proposed Removal of Low Volume or Discontinued Substances from the Revised In Commerce List

Health Canada

September 2020

Cat. No.: En14-407/2-2020E-PDF
ISBN 978-0-660-34390-7

Proposed Removal of Low Volume or Discontinued Substances from RICL.pdf [PDF - 1.01 MB]

Synopsis

Since September 14, 2001, new substances used in products regulated under the Food and Drugs Act (F&DA) have been subject to the New Substances Notification Regulations (Chemicals and Polymers) [NSNR(C&P)] and the New Substances Notification Regulations (Organisms) under the Canadian Environmental Protection Act, 1999 (CEPA). Prior to this date, substances used in products regulated under the F&DA were added to two different lists:

Existing substances used in products regulated under the F&DA between January 1, 1984 and December 31, 1986 were eligible for addition to the Domestic Substances List (DSL).
New substances that entered the Canadian market between January 1, 1987 and September 13, 2001 for use exclusively in products regulated under the F&DA were identified by Health Canada, through a process initiated in 2001, and placed on an administrative list which is now known as the Revised In Commerce List (R-ICL).

Unlike new substances that entered the Canadian market from September 14, 2001 onward for use in products regulated under the F&DA, these R-ICL substances, although subject to the NSNR, have not been requested for notification under the NSNR to date by matter of interim policy. However, Health Canada and Environment and Climate Change Canada may take appropriate action under CEPA at any time when they consider a R-ICL substance to pose a risk to human health or the environment.

As part of the Chemicals Management Plan (CMP), Health Canada has prioritized substances on the R-ICL to identify those that require further evaluation to determine whether they present a risk to human health or the environment. The scope of the R-ICL prioritization is limited to the use of substances in F&DA regulated products.

Prioritization was used to inform a subset of R-ICL substances for inclusion in a mandatory survey pursuant to section 71 of CEPA to obtain data on their recent commercial status in Canada. This survey was published in the Canada Gazette, Part I in January 2017 and contained 675 R-ICL substances that were listed in Part 4 of Schedule 1 of the survey. The scope of information gathering was limited to quantities and use patterns in F&DA product applications. The 100 kg/yr reporting threshold of the survey aligns with the 100 kg/yr minimum reporting requirement of the NSNR(C&P). Based on the results of the survey, 544 substances listed on the R-ICL were not reported as currently being imported or manufactured for use in F&DA products, or are potentially in use but at annual volumes below the NSNR triggers for reporting. These substances are listed in Appendix A of the present document.

In addition to the 544 substances mentioned above, 125 substances on the R-ICL not included in the above-mentioned mandatory survey were identified in Health Canada records as active pharmaceutical ingredients that have been discontinued, or have never been marketed, or have been approved for limited use such as substances used in research or provided through Health Canada’s Special Access Programme. These substances are listed in Appendix B of the present document.

Recent commercial status was used as an indicator to identify R-ICL substances that would be less likely to cause harm to human health or the environment as a result of their limited anticipated exposure potential. The 544 and 125 R-ICL substances listed in Appendices A and B, respectively, are consequently proposed to be removed from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other CEPA initiatives. If removed, these substances would continue to be subject to the NSNR.

1. Introduction

The Canadian Environmental Protection Act, 1999 (CEPA) (Canada 1999) is considered the cornerstone of the Government of Canada's environmental legislation. Since September 14, 2001, new substances used in products regulated under the F&DA have been subject to the New Substances Notification Regulations (Chemicals and Polymers) [NSNR(C&P)] and the New Substances Notification Regulations (Organisms) (Canada 2005a, 2005b) of CEPA.

Prior to this date, substances used in products regulated under the F&DA were added to two different lists:

Existing substances used in products regulated under the F&DA between January 1, 1984 and December 31, 1986 were eligible for addition to the Domestic Substances List (DSL).
New substances that entered the Canadian market between January 1, 1987 and September 13, 2001 for use exclusively in products regulated under the F&DA were identified by Health Canada, through a process initiated in 2001, and placed on an administrative list which is now known as the Revised In Commerce List (R-ICL) (Health Canada 2019a).

Unlike new substances that entered the Canadian market from September 14, 2001 onward for use in products regulated under the F&DA, these R-ICL substances, although subject to the NSNR, have not been requested for notification under the NSNR to date by matter of interim policy. Health Canada and Environment and Climate Change Canada may take appropriate action under CEPA at any time when they consider a R-ICL substance to pose a risk to human health or the environment.

The R-ICL contains substances used in a wide variety of applications including pharmaceuticals, medical devices, veterinary drugs, biologics (such as vaccines), natural health products, cosmetics, and food additives. The R-ICL was initially compiled from Health Canada records in 2001 and subsequently refined through a substance identity verification exercise. Substances were also added to the list through industry nominations, and the list has been periodically updated to reflect changes. In November 2019, the final nomination period to the R-ICL closed and as of March 2020 the R-ICL contains approximately 2,700 substances.

In 2016, under the Chemicals Management Plan (CMP), Health Canada prioritized the approximately 3,500 substances that were on the R-ICL at the time to identify those substances that require assessment to determine if they pose a significant risk to the environment or to human health. Identification of substances as lower priority or requiring no further consideration in the context of the R-ICL prioritization exercise was based on readily available hazard and exposure information. Prioritization of substances on the R-ICL resulted in approximately 25% of them being prioritized for further evaluation, while the remaining 75% were of reduced priority in the context of the R-ICL, including many of which were on the DSL. Those substances on the DSL have been deleted from the R-ICL to remove this redundancy. Reduced priority does not preclude actions being taken under other CEPA initiatives. A detailed document describing the approach to R-ICL prioritization was published on the CMP website on November 27, 2015 (Health Canada 2019b).

During prioritization of the R-ICL, 675 substances potentially used in products subject to the F&DA, were prioritized for further consideration based on an indication of hazard for human or environmental health and limited information on exposure which could mitigate those concerns. These 675 substances were included in Part 4 of Schedule 1 of a mandatory survey pursuant to section 71 of CEPA published in the Canada Gazette, Part I, in January 2017. The intent of this survey was to collect data on the commercial status of these substances to inform exposure potential. A 100 kg/yr reporting threshold was selected for this survey and it aligns with the 100 kg/yr minimum reporting requirement for Schedule 4 of the NSNR(C&P). The scope of information gathering was limited to quantities and use patterns for F&DA product applications. Based on the available information, 544 R-ICL substances were not reported as being manufactured or imported in Canada in F&DA product applications above the 100 kg/yr reporting threshold. These 544 R-ICL substances are identified in Appendix A.^{Footnote 1}

In addition to the substances identified in Appendix A, up to 125 substances on the R-ICL that had not been included in the above-mentioned mandatory survey were identified in Health Canada records as active pharmaceutical substances that have been discontinued, have never been marketed, or have been approved with limited use in Canada; for example, this could include substances used in research or provided through Health Canada’s Special Access Programme (Health Canada 2019c) . These 125 R-ICL substances are listed in Appendix B.

2. Assessment of commercial activity in Canada of substances on the Revised In Commerce List

2.1 Section 71 survey - Inventory update

In January 2017, a mandatory survey pursuant to section 71 of CEPA was published. The purpose of this survey was to collect more recent information on the commercial status of the substances in Canada (Canada Gazette 2017). More recent information for substances on the R-ICL was critical to support priority setting and decision making. The government was seeking further information on 675 R-ICL substances on Part 4 of Schedule 1 of the survey. The scope of the survey for R-ICL substances was limited to use in F&DA products, and information requirements pertained to use patterns and quantities in use.

Regulated parties that imported or manufactured substances listed in Part 4 of the section 71 notice at a total quantity greater than 100 kg/yr during either the 2014 or 2015 calendar year were required to respond to the survey. Figure 3 from the January 2017 section 71 notice summarizes the reporting requirements for these R-ICL substances, and is replicated in Figure 1 (Environment and Climate Change Canada 2017).

**Figure 1: Reporting diagram for each substance listed in Part 4 of the section 71 survey**

Long description

The figure provides a schematic description of the reporting requirements for Notice with respect to substances included as part of the 2017 Inventory Update using a flow diagram. The diagram is composed of multiple rectangular and oval boxes that are connected with unidirectional arrows.

Starting from the top part of the diagram, the first box asks whether you need to report for Part 4 substances. If you want to know if you need to report for a Part 4 substance, you are directed to the second box.
The second box asks whether the substance was a cosmetic, food, therapeutic product or natural health product subject to the Food and Drugs Act, or if it was contained in such a product, or intended to be a component in such a product. If your answer is yes, then you are directed to the third and fourth boxes. If your answer is no, then you are directed to the sixth box.
The third box asks whether you imported the substance in 2014 or 2015. If your answer is yes, then you are directed to the fifth box. If your answer is no, then you are directed to the sixth box.
The fourth box asks if you manufactured the substance in 2014 or 2015. If your answer is yes, then you are directed to the fifth box. If your answer is no, then you are directed to the sixth box.
The fifth box asks whether the quantity of substance imported or manufactured was greater than one hundred kilograms for 2014 or 2015. If your answer is yes, then you are directed to the seventh box. If your answer is no, then you are directed to the sixth box.
The sixth box informs you that you do not have a legal obligation to report for this activity and it directs you to the eighth and ninth box.
The seventh box asks whether you met all of the above criteria for 2015. If your answer is no, then you are directed to the tenth box. If your answer is yes, then you are directed to the eleventh box.
The eighth box encourages you to submit a Declaration of Non-Engagement if you have no involvement with a reportable substance.
The ninth box encourages you to submit a Declaration of Stakeholder Interest (for voluntary data) if you have a past, current or future interest for a reportable substance.
The tenth box informs you that you have a legal obligation to report for this activity for 2014.
The eleventh box informs you that you have a legal obligation to report for this activity for 2015.

Based on the available information, 544 R-ICL substances, which are listed in Appendix A, were identified as not being manufactured or imported in Canada, or reported quantities in F&DA product applications were less than 100 kg/yr. These 544 substances are, therefore, candidates for removal from the R-ICL.

2.2 Identification of Discontinued Pharmaceuticals

Various internal and external sources of information were used to identify 125 substances on the R-ICL, listed in Appendix B, as active pharmaceutical substances used in products which have been discontinued, never marketed, or approved with limited use in Canada. These sources were considered for pharmaceutical substances that had not been included in Part 4 of the 2017 section 71 notice (Canada Gazette 2017). These included:

Searching the Drug Product Database to identify substances no longer marketed or never approved for market in Canada (Health Canada 2019d); and
Considering internal information sources available to Health Canada to identify use patterns and quantities.

3. Conclusion

Listing on the R-ICL facilitates interim management of new substances used in F&DA regulated products introduced to the Canadian market between January 1, 1987 and September 13, 2001. The 544 R-ICL substances listed in Appendix A are substances that are of low volume based on results from a 2017 section 71 notice. The 125 active pharmaceutical substances listed in Appendix B are currently shown in Health Canada’s records as discontinued, not marketed, or approved for limited use in Canada. Given their limited anticipated exposure potential, the 544 and 125 R-ICL substances listed in Appendices A and B, respectively, are considered less likely to cause harm to human health and the environment. They are consequently proposed to be removed from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other CEPA initiatives. If removed, these substances would continue to be subject to the NSNR.

4. References

Canada. 1999. Canadian Environmental Protection Act, 1999. S.C. 1999, c.33. Canada Gazette Part III, vol. 22, no. 3.

Canada. 2005a. New Substances Notification Regulations (Chemicals and Polymers).

Canada. 2005b. New Substances Notification Regulations (Organisms).

Canada Gazette. 2017. Vol. 151, No. 2 – January 14, 2017.

Environment and Climate Change Canada. 2017. Guidance for responding to the Notice with respect to substances included as part of the 2017 Inventory Update.

Health Canada. 2019a. About the Revised In Commerce List (R-ICL).

Health Canada. 2019b. Results of the prioritization of the Revised In Commerce List.

Health Canada. 2019c. Health Canada Special Access Programme.

Health Canada. 2019d. Drug Product Database.

Appendix A

Substances proposed for removal from the R-ICL based on results of a mandatory survey pursuant to section 71 of the Canadian Environmental Protection Act, 1999 which indicate that these substances were not manufactured or imported above the reporting threshold of 100 kg/yr in either the 2014 or 2015 calendar year in F&DA regulated products
The Chemical Abstracts Service (CAS) Registry Number (CAS RN)	Substance name
53-43-0	Androst-5-en-17-one, 3-hydroxy-, (3β)-
60-31-1	Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride
66-40-0	Ethanaminium, N,N,N-triethyl-
68-05-3	Ethanaminium, N,N,N-triethyl-, iodide
79-17-4	Hydrazinecarboximidamide
85-19-8	Methanone, (5-chloro-2-hydroxyphenyl)phenyl-
85-70-1	1,2-Benzenedicarboxylic acid, 2-butoxy-2-oxoethyl butyl ester
87-18-3	Benzoic acid, 2-hydroxy-, 4-(1,1-dimethylethyl)phenyl ester
91-68-9	Phenol, 3-(diethylamino)-
94-43-9	Mercury, (benzoato-O)phenyl-
95-84-1	Phenol, 2-amino-4-methyl-
97-18-7	Phenol, 2,2'-thiobis[4,6-dichloro-
99-57-0	Phenol, 2-amino-4-nitro-
102-29-4	1,3-Benzenediol, monoacetate
102-98-7	Mercurate(2-), [orthoborato(3-)-κO]phenyl-, hydrogen (1:2)
104-98-3	2-Propenoic acid, 3-(1H-imidazol-4-yl)-
116-38-1	Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-, chloride (1:1)
122-11-2	Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-
123-78-4	4-Octadecene-1,3-diol, 2-amino-, (2S,3R,4E)-
141-02-6	2-Butenedioic acid (E)-, bis(2-ethylhexyl) ester
141-86-6	2,6-Pyridinediamine
141-94-6	5-Pyrimidinamine, 1,3-bis(2-ethylhexyl)hexahydro-5-methyl-
142-55-2	2-hydroxypropyl laurate
145-13-1	Pregn-5-en-20-one, 3-hydroxy-, (3β)-
148-79-8	1H-Benzimidazole, 2-(4-thiazolyl)-
153-61-7	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-, (6R,7R)-
306-94-5	Naphthalene, octadecafluorodecahydro-
362-74-3	Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate
500-38-9	1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-
501-30-4	4H-Pyran-4-one, 5-hydroxy-2-(hydroxymethyl)-
508-02-1	Olean-12-en-28-oic acid, 3-hydroxy-, (3β)-
518-40-1	Benzoic acid, 2-(6-hydroxy-4,5-diiodo-3-oxo-3H-xanthen-9-yl)-
522-48-5	1H-Imidazole, 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-, monohydrochloride
522-51-0	Quinolinium, 1,1'-(1,10-decanediyl)bis[4-amino-2-methyl-, dichloride
530-43-8	Hexadecanoic acid, (2R,3R)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl ester
538-02-3	Cyclopentaneethanamine, N,α-dimethyl-, hydrochloride
556-38-7	Pentanoic acid, zinc salt
557-61-9	1-Octacosanol
576-55-6	Phenol, 2,3,4,5-tetrabromo-6-methyl-
594-45-6	Ethanesulfonic acid
603-85-0	Phenol, 2-amino-3-nitro-
611-75-6	Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-, monohydrochloride
660-27-5	Acetic acid, dichloro-, compd. with N-(1-methylethyl)-2-propanamine (1:1)
719-59-5	Methanone, (2-amino-5-chlorophenyl)phenyl-
820-66-6	1-Octadecanaminium, N-(carboxymethyl)-N,N-dimethyl-, hydroxide, inner salt
832-01-9	2-Propenoic acid, 3-(4-methoxyphenyl)-, methyl ester
865-44-1	Iodine chloride (ICl₃)
866-82-0	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, copper(2++) salt (1:2)
1093-16-9	Spiro[naphthalene-2(1H),2'-oxirane]-1-propanol, α-ethenyloctahydro-α,5,5,8a-tetramethyl-
1112-38-5	Phosphorothioic acid, O,O-dimethyl ester
1314-84-7	Zinc phosphide (Zn₃P₂)
1315-04-4	Antimony sulfide (Sb₂S₅)
1317-26-6	Aluminum magnesium hydroxide (AlMg₂(OH)₇), monohydrate
1319-53-5	Malachite (Cu₂(CO₃)(OH)₂)
1322-14-1	10-Undecenoic acid, calcium salt
1399-80-0	Benzenedimethanaminium, ar-dodecyl-ar,N,N,N,N',N',N'-heptamethyl-, dichloride, mixt. with ar-dodecyl-ar,N,N,N-tetramethylbenzenemethanaminium chloride
1463-95-2	Pyridinium, 2-[2-[(5-bromo-2-pyridinyl)amino]ethenyl]-1-ethyl-6-methyl-, iodide (1:1)
1553-41-9	5,8,11,14,17-Eicosapentaenoic acid
1570-64-5	Phenol, 4-chloro-2-methyl-
1641-17-4	Methanone, (2-hydroxy-4-methoxyphenyl)(4-methylphenyl)-
1778-02-5	Pregn-5-en-20-one, 3-(acetyloxy)-, (3β)-
1929-30-2	2-Propenoic acid, 3-(4-methoxyphenyl)-, ethyl ester
1976-28-9	3-Pyridinecarboxylic acid, aluminum salt (3:1)
2016-45-7	1-Hexadecanamine, N,N-dimethyl-, hydrochloride (1:1)
2040-10-0	Ethanone, 1-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]-
2136-71-2	Ethanol, 2-(hexadecyloxy)-
2180-18-9	Acetic acid, manganese salt
2224-49-9	Dodecanoic acid, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
2315-66-4	3,6,9,12,15,18,21,24,27-Nonaoxanonacosan-1-ol, 29-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-
2370-64-1	Dodecanoic acid, 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl ester
2420-29-3	3,6,9,12,15,18-Hexaoxahexatriacontan-1-ol
2487-40-3	6H-Purin-6-one, 1,2,3,7-tetrahydro-2-thioxo-
2565-36-8	Ethanol, 2,2'-[methylenebis(oxy)]bis-
2568-33-4	1, 3-Butanediol, 3-methyl
2638-43-9	3,6,9,12,15,18,21-Heptaoxatricosan-1-ol, 23-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-
2748-88-1	Pyridinium, 4-methyl-1-tetradecyl-, chloride
2784-94-3	Ethanol, 2,2'-[[4-(methylamino)-3-nitrophenyl]imino]bis-
2835-98-5	Phenol, 2-amino-5-methyl-
2835-99-6	Phenol, 4-amino-3-methyl-
2919-66-6	Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-16-methylene-
2944-65-2	Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, iron(2+) salt (1:1)
3069-40-7	Silane, trimethoxyoctyl-
3184-65-4	Phenol, 4-chloro-2-(phenylmethyl)-, sodium salt
3251-56-7	Phenol, 2-methoxy-4-nitro-
3305-68-8	9-Octadecen-1-ol, phosphate (3:1), (9Z,9'Z,9''Z)-
3374-30-9	Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl(phenylmethyl)amino]phenyl](5-hydroxy-2,4-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-, hydroxide, inner salt, calcium salt (2:1)
3397-16-8	L-Glutamic acid, N-(1-oxooctadecyl)-
3520-90-9	3,6,9,12,15,18,21-Heptaoxatricosan-1-ol, 23-(4-octylphenoxy)-
3521-84-4	D-Glucitol, 1-deoxy-1-(methylamino)-, 3,3'-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[2,4,6-triiodobenzoate] (2:1) (salt)
3564-09-8	2,7-Naphthalenedisulfonic acid, 3-hydroxy-4-[2-(2,4,5-trimethylphenyl)diazenyl]-, sodium salt (1:2)
3599-32-4	1H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt
4316-73-8	Glycine, N-methyl-, monosodium salt
4372-02-5	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 4',5'-dibromo-3',6'-dihydroxy-, sodium salt (1:2)
4478-97-1	3,6,9,12,15-Pentaoxahentriacontan-1-ol
4618-23-9	Benzoic acid, 2,3,4,5-tetrachloro-6-(2,4,5,7-tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)-, disodium salt
4861-19-2	Urea, phosphate (1:1)
4991-65-5	1,3-Benzoxathiol-2-one, 6-hydroxy-
5353-26-4	3,6,9,12-Tetraoxatriacont-21-en-1-ol, (Z)-
5697-02-9	1-naphthalenol, 2-methyl-, acetate
5725-96-2	Methanamine, N-hydroxy-N-methyl-
5836-69-1	Phosphinic amide, P,P-dibutyl-N,N-dipropyl-
5858-61-7	2,7-Naphthalenedisulfonic acid, 3-[[4-(acetylamino)phenyl]azo]-4-hydroxy-, disodium salt
5863-51-4	Benzenemethanaminium, N-[4-[(2-chlorophenyl)[4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-, hydroxide, inner salt, sodium salt
5905-52-2	Propanoic acid, 2-hydroxy-, iron(2+) salt (2:1)
6159-41-7	10-Undecenoic acid, potassium salt (1:1)
6219-67-6	1,3-Benzenediamine, 4-methoxy-, sulfate
6219-69-8	1,3-Benzenediamine, 4-ethoxy-, sulfate
6273-99-0	Mercury, [μ-[orthoborato(2-)-κO:κO']]diphenyldi-
6358-53-8	2-Naphthalenol, 1-[(2,5-dimethoxyphenyl)azo]-
6371-76-2	2-Naphthalenecarboxylic acid, 3-hydroxy-4-(phenylazo)-, calcium salt (2:1)
6371-96-6	Butanamide, 2-[(4-methoxy-2-nitrophenyl)azo]-N-(2-methylphenyl)-3-oxo-
6505-30-2	Benzenemethanaminium, N-[4-[[4-(diethylamino)phenyl][4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-, hydroxide, inner salt, sodium salt
6548-12-5	Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl[(3-sulfophenyl)methyl]amino]phenyl](2-sulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-3-sulfo-, inner salt, barium salt (1:1)
6640-03-5	1-Tetradecanol, hydrogen phosphate
6966-09-2	Cyclohexanone, 2-(1-piperidinylmethyl)-, hydrochloride (1:1)
7091-57-8	8-Quinolinol, benzoate (salt)
7147-34-4	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tris(2-ethylhexyl)ester
7211-53-2	Docosanoic acid, potassium salt (1:1)
7230-93-5	Dodecanoic acid, aluminum salt (3:1)
7446-27-7	Phosphoric acid, lead(2++) salt (2:3)
7492-68-4	Carbonic acid, copper salt
7651-99-2	Phosphonic acid, [1,2-ethanediylbis[nitrilobis(methylene)]]tetrakis-, pentasodium salt
7789-46-0	Iron bromide (FeBr₂)
7790-44-5	Stibine, triiodo-
8007-56-5	Aqua regia
9050-93-5	β-D-Glucan, (1→3)-, carboxymethyl ether, sodium salt
9065-63-8	Oxirane, methyl-, polymer with oxirane, butyl ether
10031-23-9	Radium bromide (RaB_r2)
10031-59-1	Sulfuric acid, thallium salt
10101-63-0	Lead iodide (PbI₂)
10124-48-8	Mercury amide chloride (Hg(NH₂)Cl)
10124-49-9	Sulfuric acid, iron salt
10139-47-6	Zinc iodide (ZnI₂)
10192-46-8	Boric acid (H₃BO₃), zinc salt (2:3)
10233-14-4	9-Octadecenoic acid (Z)-, 2-[2-(2-hydroxyethoxy)ethoxy]ethyl ester
10294-31-2	Gold iodide (AuI)
10294-70-9	Tin iodide (SnI₂)
10326-21-3	Chloric acid, magnesium salt
10361-76-9	Peroxymonosulfuric acid, potassium salt (1:2)
10476-84-3	Octadecanoic acid, manganese salt (1:?)
10476-86-5	Strontium iodide (SrI₂)
11092-32-3	Aluminum oxide (AlO₂)
11108-73-9	Uranium alloy, base, U,Nb,Zr (Mulberry)
12018-01-8	Chromium oxide (CrO₂)
12122-15-5	Nickel carbonate hydroxide (Ni₅(CO₃)₂(OH)₆)
12217-41-3	C.I. Basic Blue 22
12217-43-5	9,10-Anthracenedione, 1-amino-4-[[4-[(dimethylamino)methyl]phenyl]amino]-
12221-52-2	C.I. Basic Red 22
12222-04-7	C.I. Direct Blue 199
12640-40-3	Bismuth oxide
12651-23-9	Titanium hydroxide
12684-19-4	Lead iodide
13103-75-8	Benzenamine, N,N-dimethyl-4-(2-pyridinylazo)-
13408-62-3	Ferrate(3-), hexakis(cyano-κC)-, (OC-6-11)-
13429-07-7	2-Propanol, 1-(2-methoxypropoxy)-
13557-75-0	Dodecanoic acid, 2-(1-carboxyethoxy)-1-methyl-2-oxoethyl ester, sodium salt (1:1)
13682-92-3	Aluminum, (glycinato-N,O)dihydroxy-, (ß-4)-
13779-98-1	Plumbane, tetraiodo-
14452-57-4	Magnesium peroxide (Mg(O₂))
14465-68-0	9,12,15-Octadecatrienoic acid, 1,1',1''-(1,2,3-propanetriyl) ester, (9Z,9'Z,9''Z,12Z,12'Z,12''Z,15Z,15'Z,15''Z)-
14639-25-9	2-Pyridinecarboxylic acid, chromium(3+) salt (3:1)
15763-02-7	Butanedioic acid, 2-hydroxy-, 1,4-dioctyl ester
15792-51-5	Benzenesulfonic acid, 2,5-dichloro-4-[4,5-dihydro-3-methyl-5-oxo-4-[[3-[(phenylamino)sulfonyl]phenyl]azo]-1H-pyrazol-1-yl]-, monosodium salt
15876-39-8	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,2',4',5',7'-tetrabromo-3',6'-dihydroxy, aluminum salt (3:2)
15905-86-9	Nitric acid, uranium salt
16040-38-3	Phosphoric acid, lead salt
16508-79-5	2-Naphthalenecarboxylic acid, 3-hydroxy-4-(2-phenyldiazenyl)-, barium salt (2:1)
16508-80-8	Benzoic acid, 2-(2,4,5,7-tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)-, aluminum salt (1:?)
16561-29-8	Tetradecanoic acid, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azulen-9-yl ester
16693-53-1	Glycine, N-methyl-N-(1-oxododecyl)-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
16824-78-5	Phenol, 2,4,6-trinitro-, calcium salt
17121-12-9	1,3,5,7,2,4,6,8-Tetroxatetraphosphocane, 2,4,6,8-tetrahydroxy-,2,4,6,8-tetraoxide,ion(4-)
17375-37-0	Carbonic acid, manganese salt
17619-86-2	Ethanol, 2-amino-, sulfite (salt)
17672-22-9	Phenol, 2-amino-6-methyl-
17879-97-9	Benzenepropanoic acid, 3-amino-α-ethyl-2,4,6-triiodo-, (R)-
17949-65-4	Zinc, bis(2-pyridinecarboxylato-κN¹,κO²)-, (T-4)-
18089-54-8	Silanol, methyl-
18358-13-9	2-Propenoic acid, 2-methyl-, ion(1-)
18917-91-4	Aluminum, tris(2-hydroxypropanoato-O¹,O²)-
20636-48-0	3,6,9,12-Tetraoxatetradecan-1-ol, 14-(4-nonylphenoxy)-
20858-25-7	3,6,9,12-Tetraoxatetracosanoic acid
20882-75-1	9H-Xanthen-9-one, 1,2,8-trihydroxy-6-methoxy-
21034-17-3	Oxazolium, 3,4-dimethyl-2-[2-(phenylamino)ethenyl]-, iodide
21109-95-5	Barium sulfide (BaS)
21127-45-7	3,6,9,12,15-Pentaoxaheptacosanoic acid
21245-01-2	Benzoic acid, 4-(dimethylamino)-, 3-methylbutyl ester
22366-99-0	9,10-Anthracenedione, 1-[(3-aminopropyl)amino]-4-(methylamino)-
22801-45-2	9-Octadecenoic acid (9Z)-, 2-octyldodecyl ester
23059-38-3	Cyclohexanecarboxylic acid, 1,4-dimethyl-, methyl ester, cis-
23250-42-2	Cyclohexanecarboxylic acid, 1,4-dimethyl-, methyl ester (trans)
24292-52-2	2-Propen-1-one, 1-[4-[[6-O-(6-deoxy-α-2-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-, (E)-
24545-86-6	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-dinitro-
24905-87-1	Ethanol, 2-[(4-amino-3-nitrophenyl)amino]-
25482-78-4	Peroxymonosulfuric acid, potassium salt
25709-83-5	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 2',4',5'-tribromo-3',6'-dihydroxy-
25709-84-6	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 2',4',7'-tribromo-3',6'-dihydroxy-
25852-45-3	Poly(oxy-1,2-ethanediyl), α-phosphono-ω-(dodecyloxy)-
26264-02-8	3,6,9,12-Tetraoxatetradecan-1-ol, 14-(nonylphenoxy)-
26538-44-3	1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-, [3S-(3R,7S)]-
26545-51-7	Benzamide, N,N-diethylmethyl-
26658-83-3	2-Propenoic acid, 2-methyl-, butyl ester, polymer with 2-(dimethylamino)ethyl 2-methyl-2-propenoate
26915-12-8	Benzenamine, ar-methyl-
26920-62-7	1-Docosanaminium, N-(carboxymethyl)-N,N-dimethyl-, inner salt
27177-03-3	3,6,9,12,15,18-Hexaoxaeicosan-1-ol, 20-(nonylphenoxy)-
27177-07-7	3,6,9,12,15,18,21,24,27-Nonaoxanonacosan-1-ol, 29-(octylphenoxy)-
27636-82-4	2,4-imidazolidinedione, (hydroxymethyl)-5,5-dimethyl-
27640-89-7	13-Docosenoic acid, (13Z)-13-docosen-1-yl ester, (13Z)-
28212-44-4	Poly(oxy-1,2-ethanediyl), α-(carboxymethyl)-ω-(4-nonylphenoxy)-
28261-54-3	Pyrrolidinone
28602-69-9	Diphosphoric acid, ammonium manganese(2+) salt (2:2:3)
28855-27-8	Benzenemethanaminium, ar-dodecyl-ar,N,N,N-tetramethyl-, chloride
31282-04-9	D-Streptamine, O-6-amino-6-deoxy-L-glycero-D-galacto-heptopyranosylidene-(1→2-3)-O-β-D-talopyranosyl-(1→5)-2-deoxy-N3-methyl-
31512-74-0	Poly[oxy-1,2-ethanediyl(dimethyliminio)-1,2-ethanediyl(dimethyliminio)-1,2-ethanediyl chloride (1:2)]
31846-06-7	Cyclohexanol, 3-(1,1-dimethylethyl)-, acetate
32310-26-2	Androstene
33239-19-9	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-diiodo-, sodium salt (1:2)
33907-46-9	Octadecanoic acid, hydroxy-, 2-hydroxyethyl ester
33907-47-0	Octadecanoic acid, hydroxy-, monoester with 1,2-propanediol
34464-38-5	Isodecane
34769-44-3	1,3(2H,9bH)-Dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-, sodium salt (1:1)
34965-01-0	Pyrrolidine, 1-[2-(dodecyloxy)ethyl]-, hydrochloride
35602-69-8	Cholest-5-en-3-ol (3β)-, 3-octadecanoate
37220-90-9	Silicic acid, lithium magnesium salt
37222-66-5	Potassium peroxymonosulfate sulfate (K₅(HSO₅)₂(HSO₄)(SO₄))
37286-92-3	Benzenesulfonic acid, ethenyl-, homopolymer, calcium salt
38480-64-7	1-Dodecanesulfonic acid, ion(1-)
38577-97-8	Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-diiodo-
38621-51-1	Octadecanoic acid, 12-hydroxy-, monoester with 1,2-propanediol
38866-20-5	Morpholinium, 4-[3-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1-anthracenyl)amino]propyl]-4-methyl-, methyl sulfate (1:1)
38886-21-4	Phenol, 2-methoxynitro-
38975-03-0	3,6,9,12,15-Pentaoxaheptacosanoic acid, sodium salt
39322-04-8	Chromium potassium oxide
39456-59-2	Phosphoric acid, mixt. with sodium fluoride (NaF)
40160-92-7	Poly(oxy-1,2-ethanediyl), α-(3-pentadecylphenyl)-ω-hydroxy-
40188-41-8	Octanenitrile, 3,7-dimethyl-
40738-57-6	2-Propenoic acid, ethenylidene ester, homopolymer
41080-66-4	Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-[(1-oxooctadecyl)oxy]-
41669-40-3	Tetradecanoic acid, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
41927-88-2	Sodium iodide (Na¹²³I)
49625-21-0	Butanoic acid, 4-[[4-[[[(4-methoxy-2-nitrophenyl)amino]carbonyl]amino]benzoyl]amino]-2-oxo-
50545-60-3	Phenol, methyl-, tetrabromo deriv.
50610-28-1	Ethanol, 2-[(4-amino-2-chloro-5-nitrophenyl)amino]-
50800-85-6	Indium chloride (¹¹¹InCl₃)
50982-74-6	Ethanol, 2-(4-amino-3-nitrophenoxy)-
50994-40-6	1,4-Benzenediamine, sulfate (1:?)
51023-21-3	1H-Imidazolol, ethyldihydro[(9Z)-9-octadecen-1-yl]-
51192-09-7	Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with 1,2,3-propanetriol mono-9-octadecenoate (2:1), (Z)-
51311-89-8	Antimony iodide
51365-71-0	1,2-Benzenedicarboxamide, N,N'-dioctadecyl-
51513-58-7	6,10-Dodecadienal, 3,7,11-trimethyl-, (6E)-
51781-21-6	2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, hydrochloride (1:1)
51810-70-9	Zinc phosphide
51852-65-4	Poly(oxy-1,2-ethanediyl), α-[2-hydroxy-3-[(1-oxooctadecyl)oxy]propyl]-ω-hydroxy-
52557-98-9	Bicyclo[2.2.1]heptane-2-carboxylic acid, 3,3-dimethyl-
53171-04-3	1-Propanaminium, 2-hydroxy-N,N,N-trimethyl-3-[(1-oxododecyl)oxy]-, chloride
54590-52-2	Benzenesulfonic acid, 4-dodecyl-, compd. with 1-amino-2-propanol (1:1)
55837-20-2	4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-, rel-
55852-15-8	Propanoic acid, 2-hydroxy-, compd. with N-[3-(dimethylamino)propyl]-16-methylheptadecanamide (1:1)
55901-20-7	D2-Proline, 5-oxo-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
55940-73-3	Benzoic acid, 2-hydroxy-, oxybis(methyl-2,1-ethanediyl) ester
56554-41-7	9,12,15-Octadecatrienoic acid, 2,3-dihydroxypropyl ester
56639-51-1	Aluminum, hydroxybis(tetradecanoato-κO)-
56827-95-3	1-Hexadecanol, phosphate (3:1)
57072-40-9	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, chromium(3+) salt (1:?)
57524-53-5	Ethanol, 2-[(4-methoxy-2-nitrophenyl)amino]-
57834-50-1	Benzoic acid, 4-[[[[4-(ethoxycarbonyl)phenyl]amino]methylene]amino]-, ethyl ester
57934-97-1	2-Cyclohexene-1-carboxylic acid, 2-ethyl-6,6-dimethyl-, ethyl ester
57963-76-5	4a(2H)-Naphthalenol, octahydro-4,4,8a-trimethyl-,trans-
57963-77-6	cis-1,1,10-Trimethyl-9-decahydronaphthol
58855-36-0	Ethanol, 2,2'-iminobis-, compd. with α-sulfo-ω-(dodecyloxy)poly(oxy-1,2-ethanediyl) (1:1)
59056-93-8	Ethanone, 1-[(2R,3S)-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl]-, rel-
59587-08-5	1,3-Dioxolo[4,5-g]quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-, sodium salt (1:1)
59599-53-0	Benzoic acid, 2-hydroxy-, 2-(2-hydroxy-1-methylethoxy)-1-methylethyl ester
59599-58-5	Benzenesulfonic acid, 4-tridecyl-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
59792-81-3	Aluminum, tris(5-oxo-L-prolinato-κN¹,κO²)-
59820-63-2	2-[3-(methylamino)-4-nitrophenoxy]ethanol
59970-10-4	3,6,9,12-Tetraoxatriacontan-1-ol
60031-93-8	Cyclohexanemethanol, 4-ethenyl-α,α,4-trimethyl-3-(1-methylethenyl)-, acetate, [1R-(1α,3α,4β)]-
60662-14-8^a	Indate(2-)-¹¹¹In, [N,N-bis[2 [bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, disodium
60684-33-5	2,5-Cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl-
60778-99-6	Sulfuric acid, aluminum magnesium salt
61692-77-1	2-Butenoic acid, 2-methyl-, 2-methylbutyl ester, (2Z)-
61693-08-1	Heptadecane, 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-hexadecamethyl-
61702-44-1	1,4-Benzenediamine, 2-chloro-, sulfate (1:1)
61790-62-3	Fatty acids, coco, reaction products with N,N-dimethyl-1,3-propanediamine
61886-59-7	Benzenesulfonic acid, tridecyl-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
62152-14-1	1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-, ammonium salt (1:1), homopolymer
62406-73-9	6,10-Dioxaspiro[4.5]decane, 8,8-dimethyl-7-(1-methylethyl)-
62625-14-3	Phenol, 2-amino-6-chloro-4-nitro-, monohydrochloride
63084-98-0	Phenol, 4-amino-, sulfate (2:1) (salt)
63089-86-1	Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with D-glucitol (6:1), tetra-9-octadecenoate, (all-Z)-
64924-67-0	4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-, monohydrobromide, rel-
65389-08-4	Indium-¹¹¹In, tris(8-quinolinolato-κN¹,κO⁸)-
65405-96-1	Nickel, [μ-[carbonato(2-)-κO:κO']]dihydroxydi-
66095-81-6	Ethanol, 2-[(2-methoxy-4-nitrophenyl)amino]-
66575-29-9	1H-Naphtho[2,1-b]pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, [3R-(3-α,4a-β,5-β,6-β,6a-α,10-α,10a-β,10b-α)]-
66671-82-7	1,4-Benzenediamine, 2-methoxy-, sulfate (1:1)
67783-98-6	Formaldehyde, polymer with 4,4'-(1-methylethylidene)bis[phenol] and 2-methylphenol
67846-16-6	1-Propanaminium, N-ethyl-N,N-dimethyl-3-[(1-oxooctadecyl)amino]-, ethyl sulfate
67874-65-1	Propanoic acid, 3-mercapto-, 2,3-dihydroxypropyl ester
67914-69-6	1-Piperazinecarboxylic acid, 4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, ethyl ester, rel-
68015-98-5	1,3-Benzenediamine, 4-ethoxy-, sulfate (1:1)
68239-79-2	Phenol, 3-(ethylamino)-4-methyl-, sulfate (2:1) (salt)
68239-83-8	1,4-Benzenediamine, 2-nitro-, sulfate (1:1)
68239-84-9	Phenol, 3-(diethylamino)-, sulfate (2:1) (salt)
68391-32-2	2-Naphthalenaminium, 8-[(4-amino-3-nitrophenyl)azo]-7-hydroxy-N,N,N-trimethyl-, chloride
68413-33-2	Quaternary ammonium compounds, bis(2-hydroxy-C_>10-alkyl)dimethyl, chlorides
68475-50-3	Aluminum, tris[5-amino-4-hydroxy-3-(phenylazo)-2,7-naphthalenedisulfonato(2-)]di-
68479-64-1	Butanedioic acid, 2-sulfo-, mono[2-[[(9Z)-1-oxo-9-octadecen-1-yl]amino]ethyl] ester, sodium salt (1:2)
68552-95-4	Fatty acids, vegetable-oil, ethoxylated
68797-65-9	1-Propanaminium, N-ethyl-N,N-dimethyl-3-[(1-oxodocosyl)amino]-, ethyl sulfate
68889-49-6	9-Octadecenoic acid (Z)-, 1,2,3-propanetriyl ester, polymer with α-hydro-ω-hydroxypoly(oxy-1,2-ethanediyl)
68890-92-6	Poly(oxy-1,2-ethanediyl), α-(3-carboxy-1-oxosulfopropyl)-ω-hydroxy-, ethers with lanolin alcs., disodium salts
68910-56-5	Quaternary ammonium compounds, di-C_12-15-alkyldimethyl, chlorides
68915-25-3	Keratins, lauroyl
68929-04-4	1H-Imidazolium, 1-[2-(2-carboxyethoxy)ethyl]-1-(2-carboxyethyl)-4,5-dihydro-2-undecyl-, hydroxide, disodium salt
68935-40-0	1H-Indene-2-propanoic acid, 2,3-dihydro-1-oxo-5,6-bis(phenylmethoxy)-2-propyl-
68953-59-3	Ethanaminium, 2-amino-N-(2-aminoethyl)-N-(2-hydroxyethyl)-N-methyl-, N,N'-bis(hydrogenated tallow acyl) derivs., Me sulfates (salts)
68953-68-4	Aluminum, chloro propylene glycol complexes
69537-38-8	1-Propanaminium, 2-hydroxy-N,N,N-trimethyl-3-[(1-oxodocosyl)oxy]-, chloride (1:1)
70729-87-2	Isooctadecanoic acid, compd. with N,N-dimethyl-1-dodecanamine (1:1)
71060-72-5	Quaternary ammonium compounds, tri-C_14-18-alkylmethyl, chlorides
71463-34-8	1H-Imidazolium, 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-undecyl-, hydrogen sulfate (salt), monosodium salt
71735-79-0	13-Oxabicyclo[10.1.0]trideca-4,8-diene, trimethyl-
71812-38-9	Sorbitan, isooctadecanoate (2:3)
71850-81-2	1-Propanaminium, N-(carboxymethyl)-3-[(12-hydroxy-1-oxo-9-octadecenyl)amino]-N,N-dimethyl-, hydroxide, inner salt, [R-(Z)]-
71957-08-9	Cobalt, bis(D-gluconato-κO¹,κO²)-,(T-4)-
72230-86-5	Terpenes and Terpenoids, cedarwood-oil, Texan, hydroxy, acetates
73772-45-9	1-Propanaminium, N-(carboxymethyl)-N,N-dimethyl-3-[(1-oxodecyl)amino]-, hydroxide, inner salt
73772-46-0	1-Propanaminium, N-(carboxymethyl)-N,N-dimethyl-3-[(1-oxooctyl)amino]-, hydroxide, inner salt
75018-70-1	Ethanesulfonic acid, 2-[[[[(3α,5β,7α,12α,20S)-3,7,12-trihydroxy-20-methylpregnan-21-yl]seleno-75Se]acetyl]amino]-
75911-79-4	Bicyclo[3.2.1]octan-8-ol, 1,5-dimethyl-, acetate
77851-07-1	2-Cyclohexene-1-carboxylic acid, 2,3,6,6-tetramethyl-, ethyl ester
77923-28-5	Cyclododecane, (2-methoxyethoxy)-
78509-74-7	1-(hexadecyloxy)octadecan-2-ol)
78616-98-5	Dodecanoic acid, 2-aminoethyl ester
79120-33-5	Litharge (PbO)
79702-63-9	Butanedioic acid, 2-sulfo-, mono[2-[[(9Z)-1-oxo-9-octadecen-1-yl]amino]ethyl] ester, sodium salt (1:2)
84366-81-4	Riboflavin 5'-(trihydrogen diphosphate), P'→5'-ester with adenosine, disodium salt
80435-42-3	Iron alloy, base, Fe 63-74,Cr 12.0-15.0,Ni 12.0-15.0,W 1.50-3.00,Mn 0-1.00,Si 0.30-0.80,C 0.35-0.50,Mo 0.20-0.50,P 0-0.045,S 0-0.030 (UNS S66009)
81783-01-9	6,8-Nonadien-3-one,2,4,4,7-tetramethyl-,oxime
81818-54-4	1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-
81907-73-5	3-Cyclopentene-1-acetic acid, 2,2,3-trimethyl-, ethyl ester
83615-24-1	Cholest-5-en-3-ol (3β)-, 3-isooctadecanoate
83763-47-7	Ethanol, 2-[(3-amino-4-methoxyphenyl)amino]-
83763-48-8	Ethanol, 2-[(3-amino-4-methoxyphenyl)amino]-, sulfate (1:1)
84041-77-0	Ethanol, 2,2'-[(2-nitro-1,4-phenylene)diimino]bis-
84563-62-2	Chitosan, hexanedioate (salt)
84605-12-9	13-Docosenoic acid, 13-docosenyl ester
84608-82-2	2-hydroxy-3-(oleoyloxy) propyl 5-oxo-L-prolinate
84642-57-9	Cyclopentanone, 2-[(3,3,5-trimethylcyclohexyl)acetyl]-
84753-08-2	1,3-bis(2-ethylhexyl)cyclohexane
84878-34-2	Isononanoic acid, octadecyl ester
85058-43-1	1-Piperazinecarboxylic acid, 4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, ethyl ester, rel-
85066-57-5	Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-(octadecyloxy)-
85252-25-1	Benzoic acid, 2-hydroxy-, isodecyl ester
85264-33-1	1H-Pyrazole-1-methanol, 3,5-dimethyl-
85765-48-6	Ethanol, 2-[4-[(2-aminoethyl)amino]-3-nitrophenoxy]-
86050-77-3	D-glucitol, 1-deoxy-1-(methylamino)-, [N,N-bis[2-[bis[(carboxy-κO)methyl]amino-κN]glycinato(5-)-κN,κO]gadolinate(2-) (2:1)
86419-69-4	1,2-Ethanediamine, N1-(5-methoxy-2-nitrophenyl)-, hydrochloride (1:1)
86481-08-5	Poly(oxy-1,2-ethanediyl), α, α'.-(1-methyl-1,2-ethanediyl)bis[ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]-
88103-59-7	13-Docosenoic acid, 2-octyldodecyl ester, (13Z)-
90283-04-8	1-Dodecanaminium, N-[2-(dodecyloxy)-2-oxoethyl]-N,N-dimethyl-, chloride
90529-57-0	1-Propanaminium, 3-amino-N-ethyl-N,N-dimethyl-, N-soya acyl derivs., Et sulfates
90817-34-8	2,3-Pyridinediamine, 6-methoxy-N2-methyl-
91995-81-2	Fatty acids, C_10-20and C_16-18-unsatd., reaction products with triethanolamine, di-Me sulfate-quaternized
92045-77-7	Petrolatum (petroleum), hydrotreated
92348-62-4	Octanoic acid, hydroxy-
92952-81-3	Phenol, 4-[(3-hydroxypropyl)amino]-3-nitro-
93385-13-8	Ethanol, 2-[2-[2-[2-(isohexadecyloxy)propoxy]ethoxy]ethoxy]-, acetate
93385-14-9	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-triisohexadecyl ester
93507-51-8	1-Propanaminium, 3-[(2-hydroxy-1-oxopropyl)amino]-N,N,N-trimethyl-, chloride (1:1)
93841-25-9	Benzeneethanol, 2,5-diamino-, sulfate (1:1)
94158-13-1	Ethanol, 2,2'-[(4-amino-3-nitrophenyl)imino]bis-, monohydrochloride
94158-14-2	Ethanol, 2-(1,3-benzodioxol-5-ylamino)-, hydrochloride (1:1)
94201-62-4	Docosanoic acid, 2-hydroxy-1,3-propanediyl ester
94247-26-4	Tetradecyl isooctadecanoate
94277-32-4	1,2-Hexadecanediol, 1,1'-(hydrogen phosphate), monosodium salt
94333-50-3	1-Cyclohexene-1-carboxylic acid, 2-ethyl-3,6,6-trimethyl-, ethyl ester
94333-51-4	Cyclohexanecarboxylic acid, 6-ethylidene-2,2,5-trimethyl-, ethyl ester
94400-98-3	Naphth[2,3-b]oxirene, 1a,2,3,4,5,6,7,7a-octahydro-1a,3,3,4,6,6-hexamethyl-, (1aα,4α,7aα)-
95193-70-7	Amines, N-(C_8-18 and C₁₈-unsatd. alkyl)trimethylenedi-, reaction products with 2-chloroethanol and sodium chloroacetate
95193-83-2	1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts
95371-16-7	Sulfonic acids, C_14-16-1-alkene, sodium salts
95576-89-9	1,2-Propanediol, 3-[(4-amino-2-chloro-5-nitrophenyl)amino]-
95576-92-4	1,2-Propanediol, 3,3'-[(2-chloro-5-nitro-1,4-phenylene)diimino]bis-
97375-39-8	C.I. Food Yellow 4:2
97862-76-5	Foots oil (petroleum), carbon-treated
97862-89-0	Paraffin waxes (petroleum), carbon-treated
97862-97-0	Petrolatum (petroleum), carbon-treated
97952-68-6	Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, salts with montmorillonite
99542-23-1	1-Propanaminium, N-ethyl-N,N-dimethyl-3-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]amino]-, ethyl sulfate
99610-72-7	Phenol, 2-[(2-hydroxyethyl)amino]-4,6-dinitro-
99948-86-4	2-[(dihydroxymethylsilyl)oxy]propionic acid
100418-33-5	Ethanol, 2-[(4-methyl-2-nitrophenyl)amino]-
100684-33-1	Petrolatum (petroleum), clay-treated
100684-38-6	Residual oils (petroleum), clay-treated solvent-dewaxed
100684-49-9	Slack wax (petroleum), carbon-treated
101831-37-2	Benzeneacetonitrile, 2,6-dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-
102868-96-2	Zinc, bis[N-(acetyl-κO)-L-methioninato-κO]-, (T-4)-
103622-85-1	3,6,9,12-Tetraoxatriacont-21-en-1-ol
103810-94-2	Methanone, diphenyl-, dihydroxy deriv.
104333-00-8	1,2-Propanediol, 3-[[2-nitro-4-(trifluoromethyl)phenyl]amino]-
104365-75-5	2-Propenoic acid, homopolymer, ester with 1,2,3-propanetriol
105859-93-6	Propanoic acid, 2,2-dimethyl-, tridecyl ester
105883-51-0	Copper, bis[N-(acetyl-κO)-L-methioninato-κO]-
105883-52-1	Cobalt, bis[N-(acetyl-κO)-L-methioninato-κO]-
106233-09-4	Poly(oxy-1,2-ethanediyl),α-hydro-ω-hydroxy-,mono-C_16-18-alkyl ethers, phosphates
106392-12-5	Oxirane, 2-methyl-, polymer with oxirane, block
106631-38-3	1-Naphthalenepropanol, α-ethenyldecahydro-α,5,5,8a-tetramethyl-2-methylene-
108050-54-0	Tylosin, 4A-O-de(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)-20-deoxo-20-[(3R,5S)-3,5-dimethyl-1-piperidinyl]-
108347-90-6	Poly[oxy(methyl-1-,2-ethanediyl)], α-benzoyl-ω-(octadecyloxy)-
109423-22-5	Benzoic acid, 2-hydroxy-, 5-methyl-2-(1-methylethyl)cyclohexyl ester
109485-61-2	Nonane, 2,2,4,4,6,6,8-heptamethyl-
110332-91-7	Oxirane, methyl-, polymer with oxirane, monoacetate, isohexadecyl ether, block
113010-52-9	Benzoic acid, 4-amino-, ethyl ester, polymer with oxirane
113089-59-1	Collagens, hydrolyzates, reaction products with 3-chloro-2-hydroxy-N,N,N-trimethyl-1-propanaminium chloride
113507-06-5	Milbemycin B, 5-O-demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-(methoxyimino)-, (6R,23E,25S)-
113221-73-1	2-Naphthalenecarboxaldehyde, 5,6,7,8-tetrahydro-5,5,7,8,8-pentamethyl-
115340-78-8	1-Propanaminium, 3-amino-N-ethyl-N,N-dimethyl-, N-apricot-oil acyl derivs., Et sulfates
117704-25-3	Avermectin A1a, 25-cyclohexyl-5-O-demethyl-25-de(1-methylpropyl)-
119691-49-5	1-Eicosanol, 2-tetradecyl-
119831-19-5	Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with methyl D-glucopyranoside (4:1), dioctadecanoate
120066-54-8	Gadolinium, [10-[2-(hydroxy-κO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN¹,κN⁴,κN⁷,κN¹⁰,κO¹,κO⁴,κO⁷]-
121546-77-8	Alcohols, C_12-15ethoxylate, sulfonate, sodium salt
121684-92-2	α-D-Glucopyranoside, β-D-fructofuranosyl, acetate dioctadecanoate
121734-19-8	1,3-Benzenediamine, 4-methoxy-, sulfate
121888-66-2	Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, benzoate lauryl sulfate, salts with bentonite
121888-67-3	Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, bis(hydrogenated tallow alkyl)dimethylammonium salt with hectorite
121888-68-4	Quaternary ammonium compounds, benzyl(hydrogenated tallow alkyl)dimethyl, stearates, salts with bentonite
123997-26-2	Avermectin B1, 4"-(acetylamino)-4"-deoxy-, (4"R)-
124046-05-5	Benzenemethanaminium, N-(3-aminopropyl)-N,N-dimethyl-, N-babassu-oil acyl derivs., chlorides
124046-40-8	Amides, wheat germ-oil, N-[3-(dimethylamino)propyl], lactates
125109-85-5	Benzenepropanal, β-methyl-3-(1-methylethyl)-
125804-04-8	Docosanoic acid, compd. with N-[3-(dimethylamino)propyl]docosanamide (1:1)
125804-08-2	Docosanoic acid, 2-octyldodecyl ester
125804-10-6	9,12-Octadecadienoic acid (9Z,12Z)-, dimer, compd. with (9Z,12Z)-N-[3-(dimethylamino)propyl]-9,12-octadecadienamide (1:1)
126506-93-2	1,3,2-Dioxastibolane-4,5-dicarboxylic acid, 2-hydroxy-, 2-oxide
126595-07-1	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis-, homopolymer
127061-56-7	L-Ascorbic acid, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-YL hydrogen phosphate], potassium salt (1:1)
127311-98-2	1-Propanaminium, 3-[[(9Z,12R)-12-hydroxy-1-oxo-9-octadecenyl]amino]-N,N,N-trimethyl-, chloride
128973-71-7^b	Siloxanes and Silicones, α-D-mannopyranuronoyloxy Me, hydroxy-terminated
128973-73-9	Siloxanes and Silicones, Me[1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)acetyl]oxy, hydroxy-terminated
128973-74-0	Siloxanes and Silicones, (2S-trans)-[[4-hydroxy-2-pyrrolidinyl)carbonyl]oxy] Me, hydroxyl-terminated
129496-10-2	Milbemycin, oxime
129541-40-8	Tetradecanamide, N-[3-(dimethylamino)propyl]-, phosphate (1:1)
130291-58-6	2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, homopolymer, compd. with bromomethane
130353-64-9	Quaternary ammonium compounds, coco alkyl(2,3-dihydroxypropyl)dimethyl, 3-ethers with cellulose 2-hydroxyethyl ether, chlorides
130381-02-1	Protein hydrolyzates, soya, [3-(dodecyldimethylammonio)-2-hydroxypropyl], chlorides
130381-04-3	Protein hydrolyzates, wheat germ, [3-(coco alkyldimethylammonio)-2-hydroxypropyl], chlorides
130381-05-4	Protein hydrolyzates, wheat germ, [3-(dimethyloctadecylammonio)-2-hydroxypropyl], chlorides
131044-77-4	Copper, N-acetyl-L-tyrosine hydroxy-terminated (S)-[2-(acetylamino)-3-(4-hydroxyphenyl)-1-oxopropoxy] Me siloxanes
131044-78-5	Copper, hydroxy-terminated Me (S)-[[(5-oxo-2-pyrrolidinyl) carbonyl]oxy] siloxanes 5-oxo-L-proline complexes
131216-83-6	Siloxanes and Silicones, 2-(acetylamino)-4-(methylthio)-1-oxobutyoxy Me, hydroxy-terminated
131410-48-5	Gadolinium, [5,8-bis[(carboxy-κO)methyl]-11-[2-(methylamino)-2-(oxo-κO)ethyl]-3-(oxo-κO)-2,5,8,11-tetraazatridecan-13-oato(3-)-κN⁵,κN⁸,κN¹¹,κO¹³]-
131812-48-1	1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl)-
131812-49-2	Naphthalene, 7-(diethoxymethyl)-1,2,3,4-tetrahydro-1,1,2,4,4-pentamethyl-
131812-51-6	1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-, cis-
131812-52-7	1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-, trans-
131812-67-4	1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-
132467-76-6	1-Octadecanaminium, N-[2-hydroxy-3-[3-hydroxy-4-[(3-hydroxypropyl)amino]-2,2-dimethyl-4-oxobutoxy]propyl]-N,N-dimethyl-, chloride
133934-09-5	1-Propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-wheat-oil acyl derivs., inner salts
134112-42-8	1-Propanaminium, N-[2-(dodecyloxy)-2-oxoethyl]-N,N-dimethyl-3-[(1-oxoisooctadecyl)amino]-,chloride
135326-54-4	Propanol, (tetradecyloxy)-, acetate
136207-49-3	3,6,9,12,15-Pentaoxaheptatriacontan-1-ol
136505-01-6	2-Propenenitrile, homopolymer, hydrolyzed, block, reaction products with N,N-dimethyl-1,3-propanediamine
136920-08-6	1-Propanaminium, N-(3-aminopropyl)-2,3-dihydroxy-N,N-dimethyl-, N-coco acyl derivs., chlorides
137044-11-2	1-Propanaminium, 3-[2-(acetylamino)ethoxy]-N,N,N-trimethyl-, chloride
139247-28-2	Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-hydroxy-, benzoate
142104-11-8	2-Butenedioic acid (2E)-, di-C_12-15-alkyl esters
142164-39-4	Nickel carbonate hydroxide
142891-20-1	2-Propenoic acid, 2-chloro-3-[2-chloro-5-(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)phenyl]-, ethyl ester, (2Z)-
144377-73-1	4,6-Dioxa-14-aza-10-azonia-5-phosphadotriaconta-23,26-dien-1-aminium, 5-[3-[dimethyl[3-[[(9Z,12Z)-1-oxo-9,12-octadecadien-1-yl]amino]propyl]ammonio]-2-hydroxypropoxy]-2,8-dihydroxy-N,N,10,10-tetramethyl-15-oxo-N-[3-[[(9Z,12Z)-1-oxo-9,12-octadecadien-1-yl]amino]propyl]-, 5-oxide, chloride (1:3), (23Z,26Z)-
144610-93-5	Propanoic acid, 2,2-dimethyl-, tetradecyl ester
146192-98-5	2-Butenedioic acid (2Z)-, monobutyl ester, polymer with ethenyl acetate and 1,7,7-trimethylphenylbicyclo[2.2.1]hept-2-yl 2-propenoate
146632-08-8	Siloxanes and Silicones, di-Me, Bu group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with 2-[[(heptadecafluorooctyl)sulfonyl]methylamino]ethyl acrylate and iso-Bu methacrylate
147550-61-6	Copper carbonate hydroxide
148506-50-7	Poly[oxy-1,2-ethanediyl(dimethyliminio)-1,3-propanediylimino(1,6-dioxo-1,6-hexanediyl)imino-1,3-propanediyl(dimethyliminio)-1,2-ethanediyl chloride (1:2)]
148812-63-9	Protein hydrolyzates, wheat, reaction products with palmitoyl chloride
155683-77-5	Oxirane, 2-methyl-, polymer with oxirane, monoisodecyl ether
155715-93-8	Gelatins, polymers with keratin hydrolyzates and L-lysine, hydroxy-N,N,N-trimethyl-1 propanaminium chloride-quaternized
156028-14-7	1H-Imidazolium, 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-undecyl-, inner salt, sodium salt (1:1)
156715-43-4	Protein hydrolyzates, soya, [3-(cocoalklydimethylammonio)-2-hydroxypropyl], chlorides
156798-09-3	Keratins, hydrolyzates, [3-(coco alkyldimethylammonio)-2-hydroxypropyl], chlorides
157009-77-3	9,12-Octadecadienoic acid (9Z,12Z)-, dimer, diisoeicosyl ester
158483-23-9	Poly(oxy-1,2-ethanediyl),α,α',α"-1,2,3-propanetriyltris[ω-hydroxy-,2-hydroxypropanoate
158765-79-8	Micrococcus luteus, lysate
159317-32-5	Acetic acid, hydroxy-, isooctadecyl ester
162030-43-5	Mannopyranuronic acid, 1-O-[hydroxymethyl [[(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)acetyl]oxy]silyl]-
162353-59-5	Quaternary ammonium compounds, (C_10-20and C_10-20-unsatd. alkyl) (3-chloro-2-ydroxypropyl) dimethyl, chlorides, reaction products with silk protein hydrolyzates
162888-05-3	Octadecanoic acid, 12-hydroxy-, 16-methylheptadecyl ester
165745-27-7	Carbamic acid, N-butyl-, 3-iodo-2-propyn-1-yl ester, mixt. with N-[1,3-bis(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]-N,N'-bis(hydroxymethyl)urea
169590-61-8	Protein hydrolyzates, silk, [2-hydroxy-3-(trimethylammonio)propyl], chlorides
172376-82-8	6,10-Dodecadienal, 3,7,11-trimethyl-, (6Z)-
173010-79-2	Quaternary ammonium compounds, coco alkyl(2,3-dihydroxypropyl)dimethyl, 3-phosphates (esters), chlorides, sodium salts
173763-15-0	Aluminum Sesquichlorohydrate
175357-18-3	L-Phenylalanine, N-(1-oxo-10-undecen-1-yl)-
175893-70-6	Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, diesters with caroboxymethyl wheat protein hydrolyzates
177080-35-2	Phenol, 4-[(3-hydroxypropyl)amino]-2-nitro-
179005-04-0	Siloxanes and Silicones, 3-[4-[[[3-[(2,3-dihydroxypropyl)dimethylammonio]propyl]amino]carbonyl]-2-oxo-1-pyrrolidinyl]propyl Me, di-Me, 3-[3-[[3-(C_8-22-acylamino)propyl]dimethylammonio]-2-hydroxypropyl phosphates], chlorides, sodium salts
182700-78-3	Siloxanes and Silicones, 3-[(3-aminopropyl)amino]propyl Me, di-Me, 3-hydroxypropyl Me, ethoxylated, [(hydroxydimethylsilyl)oxy]-terminated
183476-82-6	L-Ascorbic acid, 2,3,5,6-tetrakis(2-hexyldecanoate)
185018-43-3	L-Ascorbic acid, 2-[(3β)-cholest-5-en-3-yl hydrogen phosphate], monosodium salt
185429-83-8	Ethanone, 1-(1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethyl-2-naphthalenyl)-, cis-
187175-42-4	Silsesquioxanes, Me, hydroxy-terminated, alginate, compds. with caffeine
187991-39-5	L-ascorbic acid, 6-O-(dihydroxymethylsilyl)-
190270-74-7	L-Lysine dihydroxymethylsilyl ester
193888-44-7	1-Propanaminium, N-(carboxymethyl)-2-hydroxy-N-(2-hydroxyethyl)-N-[2-[(1-oxododecyl)amino]ethyl]-3-(phosphonooxy)-, inner salt, monosodium salt
193892-43-2	Poly[oxy(dimethylsilylene)], α-docosyl-ω-(docosyloxy)-
197969-51-0	1-Propanaminium, N,N,N-trimethyl-3-[(2-methyl-1-oxo-2-propen-1-yl)amino]-, chloride (1:1), polymer with methyl 2-propenoate and 2-propenoic acid
198404-98-7	Cyclopropanemethanol, 1-methyl-2-[(1,2,2-trimethylbicyclo[3.1.0]hex-3-yl)methyl]-
205537-77-5	Poly[oxy(dimethylsilylene)], α-hydro-ω-hydroxy-, mixt. with dimethicone
208126-52-7	Resin acids and Rosin acids, mixed esters with dipentaerythritol and 12-hydroxyoctadecanoic acid and stearic acid
208126-56-1	Octadecanoic acid, 12-hydroxy-, mixed esters with dipentaerythritol and isostearic acid
214047-00-4	L-Serine, N²-(1-oxohexadecyl)-L-lysyl-L-threonyl-L-threonyl-L-lysyl-
220119-17-5	Avermectin A1a, 25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-, (5Z)-
220714-63-6	Siloxanes and Silicones, di-Me, 3-hydroxypropyl Me, ethers with polyethylene glycol mono[3-(dimethyloctadecylammonio)-2-hydroxypropyl hydrogen phosphate], inner salts
223717-75-7	Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with methyl D-glucopyranoside (4:1), tri-(9Z)-9-octadecenoate
224948-78-1	Poly(oxy-1,2-ethanediyl),α-[2-[bis(2-aminoethyl)methylammonio]ethyl]-ω-hydroxy-,N,N'-di-C_14-18acyl derivs., Me sulfates (salts)
227200-22-8	L-Ascorbic acid, reaction products with methylsilanetriol and pectin
227605-22-3	Lithium magnesium sodium oxide silicate (Li0.03Mg0.39Na0.07O0.15(Si₂O₅)0.28)
243133-67-7	Poly(oxy-1,2-ethanediyl), α-(2-hydroxytetradecyl)-ω-hydroxy-,ω-C_16-18-alkyl ethers
243137-53-3	Siloxanes and Silicones, di-Me, polymers with mono[(ethenyldimethylsilyl)oxy]-terminated di-Me siloxanes
245443-07-6	L-Glutamic acid, N-(1-oxododecyl)-, mixed (3?)-cholest-5-en-3-yl 2-octyldodecyl esters
246864-39-1	Decanoic acid, 1,2,3-propanetriyl ester, reaction products with polyethylene glycol and 1,2,3-propanetriyl trioctanoate
261713-82-0^c	Poly(oxy-1,2ethanediyl),α-(2-hydoxypropyl)-ω-[1-methyl-2-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy-
288839-50-9	1-Octadecanaminium, N,N-dimethyl-N-octyl-, methyl sulfate (1:1)
305812-16-2	Poly(oxy-1,2-ethanediyl),α,α’.,α”.-1,2,3-propanetriyltris [ω-methoxy-
308068-34-0	Glycerides, C_16-18mono-, ethoxylated
308068-94-2	Imidazolium compounds, 2-C_12-14-alkyl-1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-, inner salts
308068-97-5	Onium compounds, isoquinolinium, C_12-18-alkyl, bromides
308074-11-5	Protein hydrolyzates, compds. with (Z)-N-[3-(dimethylamino)propyl]-9-octadecenamide
321735-39-1	Siloxanes and Silicones, di-Me, 3-hydroxypropyl group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with iso-Bu methacrylate
321735-42-6	Siloxanes and Silicones, di-Me, 3-hydroxypropyl group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with iso-Bu methacrylate and 2,2,2-trifluoroethyl methacrylate
329925-33-9	Oxacyclopentadec-10-en-2-one, 13-methyl-
345648-01-3	1-Propanaminium N- (3-aminopropyl) -2,3-dihydroxy-N,N-dimethyl-,N-limnanthes alba seed-oil acyl derivs., chlorides
348120-88-7	Hexanoic acid, 3,5,5 -trimethyl-, octadecyl ester
642072-46-6	Ethanol, 2,2'-iminobis-,compd. with α-sulfo-ω-(tetradecyloxy)poly(oxy-1,2-ethanediyl)
827596-80-5	Octadecanoic acid, 12-hydroxy-, polymer with oxirane, triblock
869734-19-0	acids, Cannabis sativa seed-oil, esters with polyethylene glycol ether with glycerol (3:1)
1007304-55-3	Poly(oxy-1,2-ethanediyl), ω'-hydroxy-ω-[(1- oxoisooctadecyl)oxy]-ω''-[[(5-oxo-2-pyrrolidinyl)carbonyl]oxy]- α,α',α''-1,2,3-propanediyltris-
1034015-50-3	Polysaccharides, sugarcane, 3-(dimethyloctadecylammonio)-2-hydroxypropyl ethers, chlorides
1072005-10-7	Decanoic acid, mixed diesters with octanoic acid and 1,3-propanediol
1384982-80-2	Quaternary Ammonium Compounds, dimethylbis (mixed C_12-15-alkyl and cetyl and stearyl), chlorides
1429320-75-1	Butanedioic acid, 2-sulfo-, 1(or 4)-C_10-16-alkyl esters, disodium salts

^a This substance was erroneously identified as CAS RN 139096-04-1 in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017). The correct CAS RN is listed in the table, namely CAS RN 60662-14-8.

^b The name of this substance was misspelled in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017), namely “Siloxanes and Silicones, a-D-mannopyranuronoyloxy Me, hydroxy-terminated”. The correct name is provided in the table, namely “Siloxanes and Silicones, α-D-mannopyranuronoyloxy Me, hydroxy-terminated”.

^c This substance was erroneously identified as “Poly(oxy-1,2ethanedily),α(2-hydoxypropyl)-w-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy-(9Cl)” in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017). The correct substance name is provided in the table, namely “Poly(oxy-1,2-ethanediyl), α-(2-hydroxypropyl)-ω-[1-methyl-2-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy]-”.

Appendix B

Active pharmaceutical substances proposed for removal from the R-ICL based on them having never been marketed, being discontinued or approved for limited use in Canada according to information in Health Canada records
The Chemical Abstracts Service (CAS) Registry Number (CAS RN)	Substance name
51-15-0	Pyridinium, 2-[(hydroxyimino)methyl]-1-methyl-, chloride
59-46-1	Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester
60-41-3	Strychnidin-10-one, sulfate (2:1)
63-89-8	3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)-
64-73-3	2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, monohydrochloride, (4S,4aS,5aS,6S,12aS)-
71-81-8	Benzenepropanaminium, γ-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-γ-phenyl-, iodide
83-73-8	8-Quinolinol, 5,7-diiodo-
86-75-9	8-Quinolinol, 8-benzoate
90-39-1	7,14-Methano-2H,6H-dipyrido[1,2-a:1',2'-e][1,5]diazocine, dodecahydro-, (7S,7aR,14S,14aS)-
96-83-3	Benzenepropanoic acid, 3-amino-α-ethyl-2,4,6-triiodo-
103-16-2	Phenol, 4-(phenylmethoxy)-
115-76-4	1,3-Propanediol, 2,2-diethyl-
126-27-2	Acetamide, 2,2'-[(2-hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methyl-
138-39-6	Benzenesulfonamide, 4-(aminomethyl)-
299-39-8	7,14-Methano-2H,6H-dipyrido[1,2-a:1',2'-e][1,5]diazocine, dodecahydro-, (7S,7aR,14S,14aS)-, sulfate (1:1)
302-96-5	1'H-Androstano[3,2-c]pyrazol-17-ol, 17-methyl-, ((5α,17β)-
316-42-7	2H-Benzo[a]quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-[[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]methyl]-, hydrochloride (1:2), (2S,3R,11bS)-
357-07-3	Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, hydrochloride, (5α)-
481-06-1	Naphtho[1,2-b]furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, (3S,3aS,5aS,9bS)-
483-18-1	2H-Benzo[a]quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-[[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]methyl]-, (2S,3R,11bS)-
491-58-7	9(10H)-Anthracenone, 1,8-dihydroxy-3-methyl-
513-10-0	Ethanaminium, 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethyl-, iodide
522-40-7	Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-, 1,1'-bis(dihydrogen phosphate)
552-94-3	Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester
644-62-2	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-
645-05-6	1,3,5-Triazine-2,4,6-triamine, N²,N²,N⁴,N⁴,N⁶,N⁶-hexamethyl-
977-79-7	Pregna-4,6-diene-3,20-dione, 6,17-dimethyl-
1176-08-5	Ethanamine, N,N-dimethyl-2-[2-(phenylmethyl)phenoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
1415-73-2	9(10H)-Anthracenone, 10-β-D-glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-, (10S)-
1953-02-2	Glycine, N-(2-mercapto-1-oxopropyl)-
1972-08-3	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-
2152-34-3	2-amino-5-phenyl-1,3-oxazol-4-one
2451-01-6	Cyclohexanemethanol, 4-hydroxy-α,α,4-trimethyl-, monohydrate, cis-
3385-03-3	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α,11β,16α)-
3902-71-4	7H-Furo[3,2-g][1]benzopyran-7-one, 2,5,9-trimethyl-
4419-92-5	Benzoic acid, 2-hydroxy-, compd. with N-ethylethanamine (1:1)
4697-14-7	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[2-carboxy-2-(3-thienyl)acetyl]amino]-3,3-dimethyl-7-oxo-, sodium salt (1:2), (2S,5R,6R)-
5175-83-7	Phenol, 2,4,6-tribromo-, bismuth(3+) salt (3:1)
5588-33-0	10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)-
5714-73-8	Glycine, N-benzoyl-, compd. with 1,3,5,7-tetraazatricyclo[3.3.1.13,7]decane (1:1)
5936-28-7	1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-, hydrochloride, (3S)-
7187-62-4	Quinolinium, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-
7492-32-2	Benzenepropanaminium, γ-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-γ-phenyl-
7732-97-0	Estra-1,3,5(10)-triene-3,17-diol (17β)-, diheptanoate
8015-61-0	Aloin
9002-64-6	Parathormone
9006-52-4	Tannins, albumin complexes
9039-53-6	Kinase (enzyme-activating), uro-
10417-86-4	Pregnane-3,11,20-trione, 21-hydroxy-, (5β)-
10418-03-8	2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)-
11116-97-5	Calcium, (D-gluconato)(2-hydroxypropanoato)-
13103-34-9	Androsta-1,4-dien-3-one, 17-[(1-oxo-10-undecenyl)oxy]-, (17β)-
13412-64-1	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, (2S,5R,6R)-
13838-16-9	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-
13870-90-1	Cobinamide, Co-(5'-deoxyadenosin-5'-yl)-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole-κN³)
14028-44-5	Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-
14769-73-4	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)-
15686-51-8	Pyrrolidine, 2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2R)-
20537-88-6	Ethanethiol, 2-[(3-aminopropyl)amino]-, 1-(dihydrogen phosphate)
20559-55-1	Carbamic acid, (5-propoxy-1H-benzimidazol-2-yl)-, methyl ester
21256-18-8	2-Oxazolepropanoic acid, 4,5-diphenyl-
22194-22-5	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-, (2R)-
23288-49-5	Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-
29457-07-6	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino]-3,3-dimethyl-7-oxo-, sodium salt (1:2), (2S,5R,6R)-
32093-35-9	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)-, phosphate (1:1)
33089-61-1	Methanimidamide, N'-(2,4-dimethylphenyl)-N-[[(2,4-dimethylphenyl)imino]methyl]-N-methyl-
35711-34-3	1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt (1:1)
37203-87-5	Formaldehyde, mixt. with methylphenol
37270-89-6	Heparin, calcium salt
38916-34-6	Somatostatin (sheep)
40958-31-4	Somatostatin (sheep reduced)
42116-76-7	Carbamothioic acid, N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-, O-methyl ester
49697-38-3	Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11β,16α,17β)-
50679-08-8	1-Piperidinebutanol, α-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-
52128-35-5	2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
54527-84-3	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-methyl 5-[2-[methyl(phenylmethyl)amino]ethyl] ester, hydrochloride (1:1)
56211-40-6	3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-
56767-76-1	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-, sodium salt (1:1)
59708-52-0	4-Piperidinecarboxylic acid, 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-, methyl ester
60106-89-0	2-Propanol, 1-[(1-methylethyl)amino]-3-(2-propylphenoxy)-
64211-45-6	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (1Z)-
65473-14-5	1-Naphthalenemethanamine, N-methyl-N-[(2E)-3-phenyl-2-propen-1-yl]-, hydrochloride (1:1)
65899-73-2	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-
68373-14-8	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S,5R)-
68401-82-1	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, sodium salt (1:1), (6R,7R)-
68844-77-9	1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-
69712-56-7	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7S)-
71109-09-6	1-Naphthaleneacetic acid, 4-cyclohexyl-α-methyl-
82030-87-3	Somatotropin (human), N-L-methionyl-
82752-99-6	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, monohydrochloride
87233-61-2	1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-
94218-72-1	Interleukin 2 (human clone pTIL2-21a protein moiety)
96684-40-1	β-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (5:2)
98530-76-8	Blood-coagulation factor XIVa (human protein moiety)
105816-04-4	D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-
107753-78-6	Carbamic acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester
112362-50-2	3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone, 26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-, (3R,4R,5E,10E,12E,14S,26R,26aS)-
115956-13-3	1H-Indole-3-carboxylic acid, (6R,9aS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate (1:1) (CAS name to be changed)
118390-30-0	Interferon α1 (human lymphoblast reduced), N-L-methionyl-22-L-arginine-76-L-alanine-78-L-aspartic acid-79-L-glutamic acid-86-L-tyrosine-90-L-tyrosine-156-L-threonine-157-L-asparagine-158-L-leucine-
120138-50-3	Virginiamycin S1, 4-[4-(dimethylamino)-N-methyl-L-phenylalanine]-5-[(2S,5R)-5-[[[(3S)-1-azabicyclo[2.2.2]oct-3-yl]thio]methyl]-4-oxo-2-piperidinecarboxylic acid]-
120373-24-2	5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)-
125494-59-9	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, hydrate (1:1:1)
133652-38-7	173-527-Plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine-
133814-18-3	Isoquinolinium, 2,2'-[(1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, (1R,1'S,2S,2'R)-rel-
133814-19-4	Isoquinolinium, 2,2'-[[(4E)-1,8-dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, (1R,1'R)-
136279-32-8	Interleukin 2 (human), N-L-methionyl-
138068-37-8	Hirudin (Hirudo medicinalis isoform HV1), 1-L-leucine-2-L-threonine-63-desulfo-
140678-14-4	Manganate(6-), [[N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-κO)-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycinato-κN,κO]](8-)]-, trisodium trihydrogen, (OC-6-13)-
143201-11-0	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)-
143653-53-6	Immunoglobulin G1, anti-(human integrin α_IIbβ₃) Fab fragment (human-mouse monoclonal c7E3 clone p7E3V_HhC_γ1 γ1-chain), disulfide with human-mouse monoclonal c7E3 clone p7E3V_κhC_κ κ-chain
144025-09-2	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-, (-)-
147059-72-1	1,8-Naphthyridine-3-carboxylic acid, 7-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-
147221-93-0	Methanesulfonamide, N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-, methanesulfonate (1:1)
150378-17-9	D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
152923-56-3	Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal clone 1H4 _γ1-chain), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer
153259-65-5	Cyclohexanecarboxylic acid, 4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, cis-
153559-49-0	Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-
162011-90-7	2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-
163545-26-4	1-165-Hematopoietic cell growth factor KL (human clone V19.8:hSCF162), N-L-methionyl-, dimer
165101-51-9	Becaplermin
173937-91-2	3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)-
191114-48-4	2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-
215647-85-1	Interferon α-2b (human), pegylated
219989-84-1	(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2 (2-methylthiazol-4-yl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
706808-37-9	[29-tyrosine,104-glutamic acid] CTLA-4 (antigen) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1(human monoclonal Fc domain-containing fragment), bimol. (120120')-disulfide

Footnote 1

Although there are 546 CAS RNs listed in Appendix A, there are only 544 unique substances as there are two substances that have duplicate CAS RNs. These two pairs of duplicates are: (1) CAS RNs 67914-69-6 and 85058-43-1; and (2) CAS RNs 68479-64-1 and 79702-63-9.

Return to footnote1 referrer

Footnote 2

The Chemical Abstracts Service Registry Number (CAS RN) is the property of the American Chemical Society, and any use or redistribution, except as required in supporting regulatory requirements and/or for reports to the Government of Canada when the information and the reports are required by law or administrative policy, is not permitted without the prior written permission of the American Chemical Society.

Return to footnote2 referrer

Page details

Date modified:: 2023-04-13